Entero Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Entero Therapeutics has a total shareholder equity of $77.9M and total debt of $6.8M, which brings its debt-to-equity ratio to 8.7%. Its total assets and total liabilities are $91.1M and $13.3M respectively.
Key information
8.7%
Debt to equity ratio
US$6.78m
Debt
Interest coverage ratio | n/a |
Cash | US$3.43m |
Equity | US$77.86m |
Total liabilities | US$13.27m |
Total assets | US$91.13m |
Recent financial health updates
Recent updates
First Wave BioPharma announces pricing of $6.0 million public offering
Oct 07First Wave BioPharma extends selloff after announcing strategic shift
Sep 19First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase
Sep 07First Wave BioPharma announces 1-for-30 reverse stock split
Aug 25First Wave BioPharma to raise capital in convertible preferred stocks offering
Jul 15First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment
Oct 19AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study
Jun 07AzurRx BioPharma: An Assessment
May 02AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio
Jan 31AzurRx BioPharma, First Wave Bio in niclosamide licensing pact for gastrointestinal infections
Jan 04AzurRx up 9% on advancement of mid-stage study of MS1819 in CF patients
Nov 30Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?
Nov 19Financial Position Analysis
Short Term Liabilities: ENTO's short term assets ($7.5M) exceed its short term liabilities ($6.2M).
Long Term Liabilities: ENTO's short term assets ($7.5M) exceed its long term liabilities ($7.1M).
Debt to Equity History and Analysis
Debt Level: ENTO's net debt to equity ratio (4.3%) is considered satisfactory.
Reducing Debt: ENTO's debt to equity ratio has reduced from 69.6% to 8.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ENTO has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ENTO is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.